Adeno-associated virus variants and methods of use thereof
The present disclosure provides recombinant adeno-associated virus (rAAV) virions comprising a variant AAV capsid protein, e.g., an AAV capsid protein derived from an ancestral AAV capsid protein amino acid sequence. An rAAV virion of the present disclosure can exhibit greater infectivity of a target cell. The present disclosure also provides methods of delivering a gene product to a target cell in an individual by administering to the individual an rAAV of the present disclosure. The present disclosure also provides methods of generating rAAV virions that have a variant AAV capsid protein derived from an ancestral AAV capsid protein amino acid sequence.
1. A recombinant adeno-associated virus (rAAV) virion comprising:
a) a variant AAV capsid protein, wherein the variant AAV capsid protein comprises an amino acid sequence having at least 95% amino acid sequence identity to the sequence set forth in SEQ ID NO: 16, wherein the amino acid at position 264 is a T, Q, or A, position 448 is an S or A, position 459 is a T or N, position 470 is an S or A, position 495 is an S or T, position 533 is a D or E, position 547 is a Q, E, or T, position 555 is a T or A, position 557 is an E or D, position 561 is an M, L, or I, position 563 is an S or N, position 593 is an A, Q, or V, position 596 is an A or T, position 661 is an A, E, or T, position 662 is a V, T, or A, position 664 is a T or S, position 718 is an N or S, and position 723 is an S or T; and
b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.
2. The rAAV virion of claim 1 , wherein the gene product is a polypeptide.
3. The rAAV virion of claim 2 , wherein the polypeptide is a secreted polypeptide.
4. The rAAV virion of claim 3 , wherein the secreted polypeptide is selected from the group consisting of: lipoprotein lipase, factor IX, α 1 -antitrypsin, follistatin, soluble myostatin receptor, apelin, glucagon-like peptide 1, insulin-like growth factor 1, alpha-galactosidase, iduronidase, iduronate-2-sulfatase, alpha-glucosidase, and N-acetylgalactosamine 4-sulfatase.
5. The rAAV virion of claim 2 , wherein the polypeptide is selected from the group consisting of: troponins, laminins, collagens, lamin, selenoprotein N, protein-O-mannosyltransferase, fukutin, LARGE, O-linked mannose β1,2-N-acetylglucosaminyl-transferase, and isoprenoid synthase domain-containing protein.
6. The rAAV virion of claim 1 , wherein the gene product is a genome editing gene product.
7. The rAAV virion of claim 1 , wherein the gene product is a nucleic acid gene product.
8. A pharmaceutical composition comprising:
a) a recombinant adeno-associated virus (rAAV) virion according to claim 1 ; and
b) a pharmaceutically acceptable carrier, diluent, excipient, or buffer.
9. A method of delivering a gene product to a target cell in an individual, the method comprising administering to the individual a recombinant adeno-associated virus (rAAV) virion according to claim 1 .
10. The method according to claim 9 , wherein the target cell is a muscle cell or a glial cell.
11. The method of claim 9 , wherein the gene product is a polypeptide.
12. The method of claim 9 , wherein the gene product is a nucleic acid gene product.
13. The rAAV virion of claim 1 , wherein the variant AAV capsid protein comprises an amino acid sequence having at least 95% amino acid sequence identity to the sequence set forth in SEQ ID NO: 16, and wherein the amino acids at positions 264, 448, 459, 470, 495, 533, 547, 555, 557, 561, 563, 593, 596, 661, 662, 664, 718 and 723 are A, A, N, S, S, D, E, A, E, L, N, A, A, A, T, T, N and S, respectively; Q, S, N, A, S, E, Q, T, D, M, S, Q, T, A, V, S, S and S, respectively; or A, A, T, S, T, D, Q, A, D, I, N, A, T, T, V, S, S and T, respectively.